CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2016 – CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced the selection of a third target by Bristol-Myers Squibb in accordance with the companies’ strategic oncology collaboration established in May 2014, triggering a $10 million milestone payment. …
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on our Probody™ technology platform.
Using our Probody platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class cancer therapeutics against novel targets.